Efficacy assessments
ADHD
All efficacy analyses and CSHQ assessments were analyzed using the efficacy population. This population included all enrolled subjects who received at least 30 days of study medication in the treatment phase, who had adequate data to assess the change from baseline of the efficacy parameters, and who had no protocol deviations that could affect the efficacy parameters.For new subjects, during the DO phase, the ADHD Rating Scale-5 (ADHD-RS-5), CGI-S scale, and Clinical Global Impressions–Improvement scale were used to guide DO in conjunction with tolerability and safety (Busner and Targum, The CGI-S is a clinician-rated scale that measures the severity of psychopathology (ADHD symptoms in the study) on a scale from 1 (not at all ill) to 7 (among the most extremely ill) (Busner and Targum, 